The Cancer Letter, a weekly online publication, is the leading source of information on development of cancer therapies, cancer research funding and health care finance, legislation and policy. The Cancer Letter reaches the key opinion leaders in academic oncology and in the biotechnology and pharmaceutical industries. Our audience includes faculty and staff members at cancer centers, pharmaceutic
al and biotechnology companies, government agencies, and Wall Street professionals. Based in Washington, D.C., The Cancer Letter provides in-depth coverage of events at cancer centers, the National Cancer Institute, National Institutes of Health, Food & Drug Administration, U.S. Over the past four decades, The Cancer Letter has earned acclaim and numerous journalism awards for its investigative coverage of issues that shape oncology. Our work has been profiled and cited in The New York Times, The Washington Post, 60 Minutes, 20/20, CNN, NPR, Science, Nature and many other news outlets. Our coverage has triggered investigations by Congressional committees, the Institute of Medicine, the Federal Trade Commission, the Securities and Exchange Commission, and the Department of Justice. The Cancer Letter was founded in 1973 by journalist Jerry D. Boyd, two years after Congress passed the National Cancer Act of 1971. Boyd retired in 1990, turning over the company to his daughter Kirsten Boyd Goldberg, who served as editor and publisher for the next 20 years. Paul Goldberg became publisher in January 2011.
The Cancer Letter is an award-winning weekly newsletter covering cancer research funding, legislation Congress and the pharmaceutical industry.
